Adaptive’s ImmuneMedicine platform for TCR and neoAg discovery informs therapeutic development and patient monitoring

Time: 11:30 am
day: Day Two


  • Adaptive’s core competency of sequencing and quantifying immune receptors at scale enables therapeutic discovery, development, and monitoring.
  • High-throughput, scaled discovery of neoAg specific TCRs is neoAg discovery
  • Discovery and quantification of Ag-specific, patient-specific TCRs enables informed monitoring of immune responses for vaccine development.